Drug Approval | April 06, 2022
Gufic Biosciences receives DCGI approval for Thymosin Alpha-1 to treat Covid-19
Immunocin, an Immuno-modulator drug, significantly reduced the risk of death in the Phase 3 clinical trial in adult patients with moderate-to-severe Covid-19